IP Library Granted Patent US 9,381,183
Granted Patent B2
US 9,381,183 · App. 13/815,599 · Granted Jul 5, 2016

Methods for improving the quality of the meibum composition of meibomian glands

Inventors: S. Gregory Smith (Yorklyn, DE); Michael B. Gross (Plymouth Meeting, PA); Olav E. Sandnes (Mt. Bethel, PA)
Assignee: Physicians Recommended Nutriceuticals, LLC
A61K31/202A23L1/3008A61K31/232A61K31/593
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,381,183
App. No.
13/815,599
Granted
Jul 5, 2016
Kind
B2
Abstract

This invention relates to methods for improving changing the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6's (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form.

Claims (38)

1. A method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands, comprising the steps of:

administering a composition consisting of an effective amount of omega-3 fatty acids on a daily dosage basis to a mammal having inflamed or dysfunctional meibomian glands, wherein said omega-3 fatty acids includes eirosapentaenoic acid (EPA) in an amount greater than 600 mg and comprising the triglyceride form;

increasing levels of anti-inflammatory omega-3's in a composition of meibum of said treated meibomian glands; and

decreasing levels of inflammatory omega-6's in said composition of meibum.

2. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 1 , wherein said EPA comprises an amount between 1,600 mg and 2,500 mg.

3. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 1 , wherein said EPA comprises an amount between 1,600 mg and 1,800 mg.

4. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 1 , wherein said effective amount of omega-3 fatty acids includes docosahexaenoic acid (DHA) in an amount greater than 500 mg.

5. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 4 , wherein said DHA comprises an amount between 500 mg and 900 mg.

6. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 4 , wherein said effective amount of omega-3 fatty acids comprises said amount of EPA and said amount of DHA in a 3:1 ratio.

7. The method for improving the quality of the meibum concentration of inflamed or dysfunctional meibomian glands as defined in claim 1 , further comprising the step of improving tear break up time of said mammal.

8. The method for improving the quality of the meibum concentration of inflamed or dysfunctional meibomian glands as defined in claim 1 , further comprising the step of reducing tear osmolarity of said mammal.

9. The method for improving the quality of the meibum concentration of inflamed or dysfunctional meibomian glands as defined in claim 1 , further comprising the step of improving the quality of tears of said mammal.

10. A method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands, comprising the steps of:

administering a composition consisting of an effective amount of omega-3 fatty acids on a daily dosage basis to a mammal having inflamed or dysfunctional meibomian glands, wherein said omega-3 fatty acids includes eicosapentaenoic acid (EPA) in an amount greater than 600 mg and comprising the triglyceride form;

increasing levels of anti-inflammatory omega-3's in a composition of meibum of said treated meibomian glands;

decreasing levels of inflammatory omega-6's in said composition of meibum; and

improving the quality of tears of said mammal.

11. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 10 , wherein said effective amount of EPA comprises an amount between 1,600 mg and 2,500 mg.

12. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 10 , wherein said effective amount of EPA comprises an amount between 1,600 mg and 1,800 mg.

13. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined claim 10 , wherein said effective amount of omega-3 fatty acids includes docosahexaenoic acid (DHA) in an amount greater than 500 mg.

14. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 13 , wherein said effective a mount of DHA comprises an amount between 500 mg and 900 mg.

15. The method for improving the quality of the meibum concentration of inflamed or dysfunctional meibomian glands defined in claim 13 , wherein said effective amount of EPA and said effective amount of DHA is in a 3:1 ratio.

16. A method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands, comprising the steps of:

administering a composition consisting of an effective amount of omega-3 fatty acids on a daily dosage basis to a mammal having inflamed or dysfunctional meibomian glands, wherein said omega-3 fatty acids includes eicosapentaenoic acid (EPA) in an amount greater than 600 mg and comprising the triglyceride form;

increasing levels of anti-inflammatory omega-3's in a composition of meibum of said treated meibomian glands;

decreasing levels of inflammatory omega-6's in said composition of meibum; and

improving tear break up time of said mammal.

17. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 16 , wherein said effective amount of EPA comprises an amount between 1,600 mg and 2,500 mg.

18. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 16 , wherein said effective amount of omega-3 fatty acids includes docosahexaenoic acid (DHA) in an amount greater than 500 mg.

19. The method for improving the quality of the meibum concentration of inflamed or dysfunctional meibomian glands as defined in claim 18 , wherein said effective amount of EPA and said effective amount of DHA is in a 3:1 ratio.

20. A method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands, comprising the steps of:

administering a composition consisting of an effective amount of omega-3 fatty acids on a daily dosage basis to a mammal having inflamed or dysfunctional meibomian glands, wherein said omega-3 fatty acids includes eicosapentaenoic acid (EPA) in an amount greater than 600 mg and comprising the triglyceride form;

increasing levels of anti-inflammatory omega-3's in a composition of meibum of said treated meibomian glands;

decreasing levels of inflammatory omega-6's in said composition of meibum; and

reducing tear osmolarity of said mammal.

21. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 20 , wherein said effective amount of EPA comprises an amount between 1,600 mg and 2,500 mg.

22. The method for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands as defined in claim 20 , wherein said effective amount of omega-3 fatty acids includes docosahexaenoic acid (DHA) in an amount greater than 500 mg.

23. The method for improving the quality of the meibum concentration of inflamed or dysfunctional meibomian glands as defined in claim 22 , wherein said effective amount of EPA and said effective amount of DHA is in a 3:1 ratio.

Assignments (9)
SECURITY INTEREST Recorded Aug 31, 2021
From: PRN PHYSICIAN RECOMMENDED NUTRICEUTICALS, LLC
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 057339/0669 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 032158 FRAME: 0025. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 25, 2020
From: SMITH, S GREGORY; GROSS, MICHAEL B; SANDNES, OLAV E
To: PRN PHYSICIAN RECOMMENDED NUTRICEUTICALS, LLC
Reel/Frame 052230/0358 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF ASSIGNEE PREVIOUSLY RECORDED ON REEL 032167 FRAME 0138. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 25, 2020
From: SMITH, S GREGORY; GROSS, MICHAEL B; SANDNES, OLAV E
To: PRN PHYSICIAN RECOMMENDED NUTRICEUTICALS, LLC
Reel/Frame 052230/0351 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SPELLING OF ASSIGNOR'S NAME PREVIOUSLY RECORDED ON REEL 051861 FRAME 0039. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 25, 2020
From: PRN PHYSICIAN RECOMMENDED NUTRICEUTICALS, LLC
To: PRN PHYSICIAN RECOMMENDED NUTRICEUTICALS, LLC
Reel/Frame 052230/0589 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF ASSIGNEE PREVIOUSLY RECORDED ON REEL 032167 FRAME 0110. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 23, 2020
From: SMITH, S GREGORY; GROSS, MICHAEL B; SANDNES, OLAV E
To: PRN PHYSICIAN RECOMMENDED NUTRICEUTICALS LLC
Reel/Frame 052206/0290 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2020
From: PHYSICIANS RECOMMENDED NUTRICEUTICALS LLC
To: PRN PHYSICIANS RECOMMENDED NUTRICEUTICALS LLC
Reel/Frame 051861/0039 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2014
From: SMITH, S. GREGORY; GROSS, MICHAEL B.; SANDNES, OLAV E.
To: PHYSICIAN RECOMMENDED NUTRICEUTICALS
Reel/Frame 032158/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2014
From: SMITH, S. GREGORY; GROSS, MICHAEL B.; SANDNES, OLAV E.
To: PHYSICIANS RECOMMENDED NUTRICEUTICALS LLC
Reel/Frame 032167/0138 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2014
From: SMITH, S. GREGORY; GROSS, MICHAEL B.; SANDNES, OLAV E.
To: PHYSICIANS RECOMMENDED NUTRICEUTICALS LLC
Reel/Frame 032167/0110 →
Continuity (2)
Continuation In Part 13507673 · Jul 18, 2012
Related Publication 20140024625A1 · Jan 23, 2014